Claims for Patent: 8,633,034

Summary for Patent: 8,633,034

Title:	Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
Abstract:	This invention relates to methods for evaluating or inhibiting the aggregation of a protein in an aqueous suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution including sugar and a non-ionic surfactant.
Inventor(s):	Trotter; Joseph T. (La Jolla, CA), Hamel; Jean-Bernard (Saint Cassien, FR), Carpenter; John Frank (Littleton, CO), Randolph; Theodore (Niwot, CO), Gabrielson; John Paul (Longmont, CO)
Assignee:	Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO)
Application Number:	12/739,009
Patent Claims:	1. A method for evaluating the aggregation of a proteinaceous material in a suspension comprising an organopolysiloxane, comprising: (a) providing an aqueous suspension of a fluorescently-labeled organopolysiloxane and a fluorescently-labeled proteinaceous material; (b) measuring relative particle fluorescence intensity of the fluorescently-labeled organopolysiloxane and the fluorescently-labeled proteinaceous material using fluorescence-activated particle sorting; and (c) evaluating the aggregation of the proteinaceous material by comparing the relative intensity of the fluorescently-labeled organopolysiloxane to the relative intensity of the fluorescently-labeled proteinaceous material, wherein the relative intensity of the fluorescently-labeled organopolysiloxane as compared to the relative intensity of the fluorescently-labeled proteinaceous material indicates the aggregation of the proteinaceous material. 2. The method according to claim 1, wherein the fluorescently-labeled proteinaceous material comprises at least one proteinaceous material which is a monoclonal antibody. 3. The method according to claim 2, wherein the monoclonal antibody is selected from the group consisting of infliximab, basiliximab, abciximab, daclizumab, gemtuzumab, alemtuzumab, rituximab, palivizumab, trastuzumab and etanercept. 4. The method according to claim 1, wherein the organopolysiloxane is labeled with a first fluorescent moiety which emits light within a first range of wavelengths and the proteinaceous material is labeled with a second fluorescent moiety which emits light within a second range of wavelengths when the first fluorescent moiety and the second fluorescent moiety are each exposed to light of the same wavelength emitted by a laser, wherein the first range of wavelengths is substantially free of overlap with the second range of wavelengths. 5. The method according to claim 4, wherein the first range of wavelengths overlap with the second range of wavelengths less than 5% on a basis of total combined normalized range of wavelengths of the first range of wavelengths and the second range of wavelengths. 6. The method according to claim 1, wherein the organopolysiloxane is labeled with Nile Red fluorescent moiety which emits undetectable levels of light over a range of 450 nm to 650 nm and the proteinaceous material is labeled with Pacific Blue dye which emits light over a range of 340 nm to 450 nm when exposed to a 405 nm violet laser. 7. The method according to claim 1, wherein the aqueous suspension further comprises at least one non-ionic surfactant. 8. The method according to claim 7, wherein the non-ionic surfactant is selected from the group consisting of acetylenic glycols, alkanolamides, alkanolamines, alkyl phenols, fatty acids, fatty alcohols, fatty esters, glycerol esters, monododecyl ethers, phenol derivatives, poloxamers, poloxamines, polyoxyethylene acyl ethers, polyoxyethyleneglycol dodecyl ethers, sodium dodecyl sulfates, sorbitols, sorbitan derivatives and mixtures thereof. 9. The method according to claim 8, wherein the non-ionic surfactant is a sorbitan derivative selected from the group consisting of sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters and mixtures thereof. 10. The method according to claim 1, wherein the aqueous suspension further comprises at least one sugar. 11. The method according to claim 7, wherein the aqueous suspension further comprises at least one sugar. 12. The method according to claim 10, wherein the sugar is selected from the group consisting of monosaccharides, disaccharides, trisaccharides, oligosaccharides and mixtures thereof. 13. The method according to claim 12, wherein the sugar is selected from the group consisting of sucrose, lactose, fructose, glucose, galactose, mannose, mannose and mixtures thereof. 14. The method according to claim 9, wherein the non-ionic surfactant is a polyoxyethylene sorbitan fatty acid ester and further comprising a sugar which is sucrose. 15. The method according to claim 1, further comprising providing a plurality of aqueous suspensions of a fluorescently-labeled organopolysiloxane and a fluorescently-labeled proteinaceous material, wherein each aqueous suspension further comprises at least one aggregation inhibitor selected from the group consisting of non-ionic surfactants and sugars wherein a concentration of the at least one aggregation inhibitor is different in each aqueous suspension, measuring relative particle fluorescence intensity of the fluorescently-labeled organopolysiloxane and the fluorescently-labeled proteinaceous material in each aqueous suspension using fluorescence-activated particle sorting; and comparing the relative intensity of the fluorescently-labeled organopolysiloxane to the relative intensity of the fluorescently-labeled proteinaceous material for each aqueous suspension. 16. The method according to claim 1, further comprising providing a plurality of aqueous suspensions of a fluorescently-labeled organopolysiloxane and a fluorescently-labeled proteinaceous material, wherein each aqueous suspension further comprises at least one aggregation inhibitor selected from the group consisting of non-ionic surfactants and sugars wherein the at least one aggregation inhibitor is different in each aqueous suspension, measuring relative particle fluorescence intensity of the fluorescently-labeled organopolysiloxane and the fluorescently-labeled proteinaceous material in each aqueous suspension using fluorescence-activated particle sorting; and comparing the relative intensity of the fluorescently-labeled organopolysiloxane to the relative intensity of the fluorescently-labeled proteinaceous material for each aqueous suspension. 17. The method according to claim 15, further comprising selecting at least one aggregation inhibitor for use in a suspension comprising a proteinaceous material based upon the comparison of the relative intensity of the fluorescently-labeled organopolysiloxane to the relative intensity of the fluorescently-labeled proteinaceous material for each aqueous suspension. 18. The method of claim 1, in which the relative particle fluorescence intensity of the fluorescently-labeled organopolysiloxane and the fluorescently-labeled proteinaceous material using fluorescence-activated particle sorting is measured in a flow cytometer and aggregation is evaluated from data output of the flow cytometer. 19. The method of claim 18, in which light scattering data for the particles is measured and the aggregation of the light scattering data is used with fluorescent intensity data to produce an output.

Details for Patent 8,633,034

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2027-06-25
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-06-25
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-06-25